Aichi, Japan

Masashi Ohmi

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations of Masashi Ohmi in Pharmaceutical Development

Introduction

Masashi Ohmi is a notable inventor based in Aichi, Japan, recognized for his contributions to pharmaceutical innovations. With a total of six patents to his name, he has made significant strides in the field of drug development, particularly in the area of CRHR2 antagonists.

Latest Patents

Ohmi's latest patents include the development of 3-hydroxyoxindole derivatives as CRHR2 antagonists. This invention focuses on compounds that exhibit antagonistic activities against CRHR2, which are beneficial in treating or preventing various disorders and diseases associated with this receptor. Additionally, he has patented fused cyclic urea derivatives that also act as CRHR2 antagonists, providing further options for pharmaceutical compositions aimed at treating conditions linked to CRHR1 and CRHR2.

Career Highlights

Throughout his career, Masashi Ohmi has worked with prominent companies in the pharmaceutical industry, including Raqualia Pharma Inc. and Xuanzhu Pharma Co., Ltd. His work has been instrumental in advancing therapeutic options for patients suffering from conditions related to CRHR receptors.

Collaborations

Ohmi has collaborated with esteemed colleagues such as Yuji Shishido and Kazuo Ando, contributing to a rich exchange of ideas and innovations in the pharmaceutical sector.

Conclusion

Masashi Ohmi's innovative work in developing CRHR2 antagonists showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of various disorders, highlighting the importance of continued research and development in pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…